Primary open-angle glaucoma (POAG) or Ocular hypertension (OH)
Conditions
Interventions
0.1% SNJ-2022 instilled in both eyes, b.i.d. for 4 weeks.
0.15% SNJ-2022 instilled in both eyes, b.i.d. for 4 weeks.
Vehicle instilled in both eyes, b.i.d. for 4 weeks.
Sponsors
Senju Pharmaceutical co.,ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients had POAG or OH 2)Patients who needs the treatment with eye drops in both eyes 3)Patients were likely to be controlled on glaucoma medication 4)IOP (hour 0) POAG:IOP of >=18.0 mmHg and <= 31.0 mmHg OH:IOP of >= 22.0 mmHg and <= 31.0 mmHg 5)Best corrected visual acuity of 0.7 or better
Exclusion criteria
Exclusion criteria: 1)Any active ocular disease other than glaucoma or OH 2)Active retinal disease 3)History of keratorefractive surgery, filtering surgery, trabeculotomy in the study eye 4)Ocular surgery within 3 months in the study eye 5)Use of contact lenses 6)Allergy or serious side effect to alpha2-adrenergic agonist 7)Use of alpha-adrenoceptor agonist, alpha-adrenoceptor antagonist, beta-adrenergic agonist, beta-adrenoceptor antagonist, MAO inhibitor, adrenergic-augmenting psychotropic drugs, Central Nervous System Depressant 8)Patient with Impaired liver function, kidney disorder, depression, raynaud disease, thromboangiitis obliterans, orthostatic hypotension, cerebrovascular occlusion, coronary vessel occlusion, compromised circulation of serious cardiovascular disease 9)Women who were pregnant, nursing or who were of childbearing potential, or planning a pregnancy 10)Highly visual field loss 11)Corneal abnormalities that would preclude accurate readings with an applanation tonometer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline intraocular pressure (IOP) at last visit (Hour 0 and 2) | — |
Countries
Japan
Contacts
Public ContactYoko Minagawa
Senju Pharmaceutical co.,ltd. Clinical Development
Outcome results
None listed